ImmunityBio (IBRX) Net Income Attributable to Noncontrolling Interests (2020 - 2026)
ImmunityBio's Income from Non-Controlling Interests was -$12,000 in Q2 2026, compared with -$19,000 a year earlier.
Powered by 
Analysis
ImmunityBio (IBRX) Net Income Attributable to Noncontrolling Interests (2020 - 2026) Analysis & Trends
On a trailing twelve-month basis, ImmunityBio's Income from Non-Controlling Interests was -$62,000 through Jun 30, 2026; for FY2025, it came in at -$74,000.
- In earlier years, Income from Non-Controlling Interests was -$81,000 in FY2024, -$656,000 in FY2023, -$753,000 in FY2022 and -$3.06 million in FY2021.
- The Q2 2026 figure marks the highest quarterly Income from Non-Controlling Interests in data going back to Q1 2020.
- Per Business Quant data, IBRX's Income from Non-Controlling Interests in the three quarters before Q2 2026 was -$15,000 (Q1 2026), -$14,000 (Q4 2025) and -$21,000 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCI Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | - |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | - |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 2.00 Mn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 2.00 Mn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | -1.00 Mn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | - |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | - |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 10.00 Mn |
| 10 | ImmunityBio | 7.17 Bn | 5.86 Bn | 47.55 Mn | -15,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -15,000.00 |
| Jun 30, 2026 | -12,000.00 |
| Mar 31, 2026 | -15,000.00 |
| Dec 31, 2025 | -14,000.00 |
| Sep 30, 2025 | -21,000.00 |
| Jun 30, 2025 | -19,000.00 |
| Mar 31, 2025 | -20,000.00 |
| Dec 31, 2024 | -17,000.00 |
| Sep 30, 2024 | -23,000.00 |
| Jun 30, 2024 | -20,000.00 |
| Mar 31, 2024 | -21,000.00 |
| Dec 31, 2023 | -22,000.00 |
| Sep 30, 2023 | -60,000.00 |
| Jun 30, 2023 | -334,000.00 |
| Mar 31, 2023 | -240,000.00 |
| Dec 31, 2022 | -111,000.00 |
| Sep 30, 2022 | -223,000.00 |
| Jun 30, 2022 | -247,000.00 |
| Mar 31, 2022 | -172,000.00 |
| Dec 31, 2021 | -294,000.00 |
API Access
ImmunityBio Net Income Attributable to Noncontrolling Interests API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=IBRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-non-controlling-interests", "ticker": "IBRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=IBRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();